[1]殷云杰,徐 亮,徐 辰,等.C反应蛋白-甘油三酯葡萄糖指数与冠状动脉支架内再狭窄的相关性[J].介入放射学杂志,2026,(09):1026-1031.[doi:10.3969/j.issn.1008-794X.2026.09.010]
　YIN Yunjie,XU Liang,XU Chen,et al.The correlation between C-reactive protein-triglyceride-glucose index and in-stent restenosis after coronary artery stenting[J].J Intervent Med,2026,(09):1026-1031.[doi:10.3969/j.issn.1008-794X.2026.09.010]
点击复制

C反应蛋白-甘油三酯葡萄糖指数与冠状动脉支架内再狭窄的相关性()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2026年09
页码:
1026-1031
栏目:
临床研究
出版日期:
2026-09-10

文章信息/Info

Title:
The correlation between C-reactive protein-triglyceride-glucose index and in-stent restenosis after coronary artery stenting
文章编号:
1008-794X(2026)-009-1026-06
作者:
殷云杰;  徐 亮;  徐 辰;  张瑞岩;  韩 琳;  陈燕春
214200 江苏宜兴 宜兴市人民医院心内科(殷云杰、徐 亮、徐 辰、韩 琳、陈燕春); 上海交通大学医学院附属瑞金医院心内科(张瑞岩)
Author(s):
YIN Yunjie; XU Liang; XU Chen; ZHANG Ruiyan; HAN Lin; CHEN Yanchun.
Department of Cardiology,Yixing Municipal People's Hospital,Yixing,Jiangsu Province 214200,China
关键词:
C反应蛋白-甘油三酯葡萄糖指数;  冠状动脉支架植入术;  支架内再狭窄
分类号:
R541.4
DOI:
10.3969/j.issn.1008-794X.2026.09.010
文献标志码:
B
摘要:
目的 研究C反应蛋白-甘油三酯葡萄糖指数(C-reactive protein-triglyceride-glucose index,CTI)与经皮冠状动脉介入治疗(PCI)术后支架内再狭窄(in-stent restenosis,ISR)的相关性及其预测价值。方法 该研究为回顾性病例对照研究,选择2016年1月至 2024年6月在宜兴市人民医院心内科住院的PCI术后患者492例,所有纳入患者均行冠状动脉造影(coronary angiography,CAG)确定是否存在ISR,收集临床资料,CAG术前检测血常规、血生化、随机血糖、糖化血红蛋白等。根据CAG结果分组,即非ISR组(427例)和ISR组(65例)。采用限制性立方条样(RCS)分析CTI与ISR的非线性关系; 采用logistic回归分析ISR的相关危险因素; 采用受试者工作曲线(ROC)分析相关指标对ISR的预测效能。结果 CTI水平在ISR组明显升高; RCS分析显示,CTI与ISR不呈现非线性关系(P=0.304),曲线接近线性相关; 调整年龄、性别、高血压史、糖尿病史、吸烟史后,仍然呈现线性相关(P=0.307)。单因素logistic回归分析提示CTI是ISR的危险因素(OR=2.85,P<0.05); 多因素logistic回归校正性别、年龄、吸烟、饮酒、高血压、糖尿病后,CTI仍然是ISR的危险因素(OR=1.82,P<0.05)。ROC分析结果显示,CTI ROC曲线下面积为0.71(95%CI:0.64～0.77,P<0.001); 通过计算约登指数,CTI的ROC曲线上最佳截断点为8.86,对应的灵敏度和特异度分别为87.7%、47.1%。结论 术前CTI升高与PCI术后ISR的发生存在相关性,且高水平CTI是PCI术后发生ISR的独立危险因素。

参考文献/References:

[1] Borovac JA,D'Amario D,Vergallo R,et al.Neoatherosclerosis after drug-eluting stent implantation:a novel clinical and therapeutic challenge[J].Eur Heart J Cardiovasc Pharmacother,2019,5:105-116.
[2]Aoki J,Tanabe K.Mechanisms of drug-eluting stent restenosis[J].Cardiovasc Interv Ther,2021,36:23-29.
[3]Ullrich H,Olschewski M,Münzel T,et al.Coronary in-stent restenosis:predictors and treatment[J].Dtsch Arztebl Int,2021,118:637-644.
[4]Zhang J,Zhang Q,Zhao K,et al.Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease:a retrospective observational study[J].Medicine,2022,101:e31707.
[5]林玉平,魏 芹,徐卫峰,等.脂蛋白a和同型半胱氨酸对冠状动脉支架内再狭窄影响的临床分析[J].介入放射学杂志,2022,31:597-600.
Lin YP,Wei Q,Xu WF,et al.Clinical analysis of the influence of lipoprotein(a)and homocysteine on coronary in-stent restenosis[J].J Interv Radiol,2022,31:597-600.
[6]Xu M,Zhang LY,Xu D,et al.Usefulness of C-reactive protein-triglyceride glucose index in detecting prevalent coronary heart disease:findings from the National Health and Nutrition Examination Survey 1999-2018[J].Front Cardiovasc Med,2024,11:1485538.
[7]Ruan GT,Xie HL,Zhang HY,et al.A novel inflammation and insulin resistance related indicator to predict the survival of patients with cancer[J].Front Endocrinol,2022,13:905266.
[8]Giustino G,Colombo A,Camaj A,et al.Coronary in-stent restenosis[J].J Am Coll Cardiol,2022,80:348-372.
[9]徐帅磊,乔 勇,汤成春,等.冠状动脉支架内再狭窄危险因素研究进展[J].东南大学学报(医学版),2023,42:475-480.
Xu SL,Qiao Y,Tang CC,et al.Advances in research on risk factors for coronary In-stent restenosis[J].J Southeast Univ Med Sci Ed,2023,42:475-480.
[10]闫启鹍,王亚斌,曹 丰,等.冠状动脉支架内再狭窄及其危险因素概述[J].中华老年多器官疾病杂志,2021,20:697-701.
Yan QK,Wang YB,Cao F,et al.Review of coronary in-stent restenosis and its risk factors[J].Chin J Mult Organ Dis Elder,2021,20:697-701.
[11]Ceresnakova M,Murray D,Soulimane T,et al.Candidates for smart cardiovascular medical device coatings:a comparative study with endothelial and smooth muscle cells[J].Eur J Pharmacol,2021,910:174490.
[12]Baktashian M,Saffar Soflaei S,Kosari N,et al.Association of high level of hs-CRP with in-stent restenosis:a case-control study[J].Cardiovasc Revasc Med,2019,20(7):583-587.
[13]Rai H,Reddi R,Coughlan JJ,et al.Pre-percutaneous coronary intervention C-reactive protein levels and in-stent restenosis:a systematic review and Meta-analysis[J].Health Sci Rep,2025,8:e70757.
[14]Cheng G,Chang FJ,Wang Y,et al.Factors influencing stent restenosis after percutaneous coronary intervention in patients with coronary heart disease:a clinical trial based on 1-year follow-up[J].Med Sci Monit,2019,25:240-247.
[15]Rizo-Tellez SA,Sekheri M,Filep JG.C-reactive protein:a target for therapy to reduce inflammation[J].Front Immunol,2023,14:1237729.
[16]Jakubiak GK,Pawlas N,Cies'lar G,et al.Pathogenesis and clinical significance of in-stent restenosis in patients with diabetes[J].Int J Environ Res Public Health,2021,18:11970.
[17]Nishio K,Sakurai M,Kusuyama T,et al.A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes[J].Diabetes Care,2006,29:101-106.
[18]张 斌,张亚豪,郑绪伟,等.糖化血红蛋白变异性与2型糖尿病患者PCI术后支架内再狭窄的相关性分析[J].临床心血管病杂志,2022,38:186-191.
Zhang B,Zhang YH,Zheng XW,et al.Correlation between glycosylated hemoglobin variability and in-stent restenosis after PCI in patients with type 2 diabetes[J].J Clin Cardiol,2022,38:186-191.
[19]Wang P,Xu J.Predictive scoring model for in-stent restenosis risk in coronary artery disease patients[J].Med Sci Monit,2025,31:e947986.
[20]Li Y,Jin P,Hou F,et al.Association between TG-to-HDL-C ratio and in-stent stenosis under optical coherence tomography guidance[J].J Med Syst,2018,43:4.
(收稿日期:2025-11-06)
(本文编辑:元 禾)

备注/Memo

备注/Memo:
基金项目: 无锡市卫健委重大项目(Z202305); 无锡市科协软科学研究课题(KX-25-B62); 江苏省老年医学学会科研项目(JGS2025MS007)
通信作者: 陈燕春 E-mail:staff890@yxph.com
更新日期/Last Update: 2026-09-25